Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1057P - ROS1 mutation can serve- as a potential efficacious predictor of immunotherapy in melanoma patients


16 Sep 2021


ePoster Display


Tumour Site



Hucheng Liu


Annals of Oncology (2021) 32 (suppl_5): S867-S905. 10.1016/annonc/annonc706


H. Liu1, J. Zeng1, J. Xiao1, D. Fan2, Y. Chen2, M. Huang3

Author affiliations

  • 1 Department Of Bone Oncology, the First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
  • 2 The Medical Department, 3D Medicines Inc., 201100 - Shanghai/CN
  • 3 Medical Marketing Department, 3D Medicines Inc., 201114 - Shanghai/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1057P


Melanoma is a serious skin cancer. Immune checkpoint inhibitors (ICIs) including atezolizumab, pembrolizumab, nivolumab, ipilimumab have shown durable responses and have been approved by FDA. However, ICIs demonstrate antitumor effects only in a fraction of patients, and research exploring the association between gene mutation and clinical benefit is limited. ROS1 mutation rate is high in melanoma. Studies have shown that ROS1 substitutions/indels correlated with higher TMB (Tumor Mutation Burden) and PD-L1+/TMB-H proportions than wild-type genotypes in NSCLC, which means that the mutation of ROS1 gene may be related to the efficacy of immunotherapy in patients with NSCLC, but the association between ROS1 mutation and TMB or survival in melanoma is unknown.


The association between ROS1 mutation with TMB and survival data was analyzed in melanoma patients from the public immunotherapy-treated cohort called Melanoma.Allen2015.WES.110, which worked as training cohort while the validation cohort1 was retrieved from Pancancer.Samstein2018.NGS.1661 and validation cohort2 was from Melanoma.Hugo2016.WES.38. Wilcoxon test was used for the comparison of TMB. Overall survival (OS) analyses were conducted in the public cohort using Kaplan-Meier curves and log-rank tests. Statistical significance was set at p=0.05.


In the training cohort, 18.2% (20/110) melanoma patients harbored ROS1 mutation. ROS1 mutation is associated with higher TMB (p=0.00002). Survival analysis demonstrates that ROS1 mutation results in significantly longer OS (21.75 vs 7.65 months; HR, 0.55; p=0.046) in melanoma patients treated with ICIs. While the validation cohort1 shows that 20.1% (63/313) melanoma patients harbored ROS1 mutation,which results in an increasing trend on TMB with strongly significant difference (p=1.32*e-17)and significantly longer OS (19 vs 18 months; HR, 0.58; p=0.041). Besides, validation cohort2 also shows that ROS1 mutation results in an higher TMB with significant difference (p=0.017) and significantly longer OS (26.6 vs 14.4 months; HR, 0.25; p=0.045).


This study shows that ROS1 mutation is correlated with higher TMB in melanoma and serves as a predictive biomarker of ICI benefit in melanoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


D. Fan: Financial Interests, Personal and Institutional, Member: 3DMed. Inc.. Y. Chen: Financial Interests, Personal and Institutional, Member: 3DMed. Inc.. M. Huang: Financial Interests, Personal and Institutional, Member: 3DMed. Inc.. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.